Page last updated: 2024-08-23

sisomicin and Pneumonia, Ventilator-Associated

sisomicin has been researched along with Pneumonia, Ventilator-Associated in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Nambiar, S; Schumann, K; Walinsky, S1
Kidd, JM; Kuti, JL; Nicolau, DP1
Connolly, LE; Daikos, GL; Dwyer, JP; Friedland, I; Jubb, AM; Krause, KM; McKinnell, JA; Serio, AW; Smith, A; Talbot, GH1

Reviews

1 review(s) available for sisomicin and Pneumonia, Ventilator-Associated

ArticleYear
Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:4

    Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Pneumonia, Ventilator-Associated; Sisomicin

2018

Trials

1 trial(s) available for sisomicin and Pneumonia, Ventilator-Associated

ArticleYear
Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.
    The New England journal of medicine, 2019, 02-21, Volume: 380, Issue:8

    Topics: Anti-Bacterial Agents; Bacteremia; Carbapenem-Resistant Enterobacteriaceae; Colistin; Creatinine; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Healthcare-Associated Pneumonia; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sample Size; Sisomicin

2019

Other Studies

1 other study(ies) available for sisomicin and Pneumonia, Ventilator-Associated

ArticleYear
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.
    Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:4

    Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration

2021